参考文献/References:
[1] Atraszkiewicz D, Ito R, Bahra A.The efficacy of botulinum toxin type-A for intractable chronic migraine patients with no pain-free time[J]. Br J Pain, 2022, 16(1): 41-49.
[2] Headache classification committee of the international headache society(IHS), the international classification of headache disorders, 3rd edition[J]. Cephalalgia, 2018, 38(1): 1-211.
[3] Lee WH, Shin Tj, Kim HJ, et al. Intrathecal administration of botulinum neurotoxin type A attenuates formalin-induced nociceptive responses in mice[J]. AnesthAnalg, 2011, 112(1): 228-235.
[4] Huang P, Khan I, Suhail M, et al.Spinal botulinum neurotoxin B:effects on afferent transmitter release and nociceptive processing[J]. PLoS One, 2011, 6:e19126.
[5] Wager TD, Scott DJ, Zubieta JK. Placebo effects on human mu-opioid activity during pain[J].PNAS, 2007, 104(26):11056-1061.
[6] Domínguez VC, Leira Y, Saavedra PM, et al. Iron deposits in periaqueductal gray matter are associated with poor response to onabotulinumtoxinA in chronic migraine[J]. Toxins(Basel), 2020, 12(8): 479.
[7] Haider L. Inflammation, iron, energy failure, and oxidative stress in the pathogenesis of multiple sclerosis[J]. Oxid Med Cell Longev, 2015, 2015: 725370.
[8] Won SM, Lee JH, Park UJ, et al. Iron mediates endothelial cell damage and blood-brain barrier opening in the hippocampus after transient forebrain ischemia in rats[J]. Exp Mol Med, 2011, 43(2): 121-128.
[9] Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence,disability,and sociodemographic factors:results from the american migraine prevalence and prevention study[J]. Headache, 2012(52): 1456-1470.
[10] Louter MA, Bosker JE, Van Oosterhout WP, et al. Cutaneous allodynia as a predictor of migraine chronification[J]. Brain, 2013(136): 3489-3496.
[11] Xu J, Kong F, Buse DC. Predictors of episodic migraine transformation to chronic migraine:a systematic review and meta-analysis of observational cohort studies[J]. Cephalalgia, 2020, 40(5): 503-516.
[12] Ray JC, Hutton EJ, Matharu M. OnabotulinumtoxinA in migraine: a review of the literature and factors associated with efficacy[J]. J Clin Med, 2021, 10(13): 2898.
[13] Blumenfeld A, Silberstein SD, Dodick DW, et al. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program[J]. Headache, 2010, 50(9): 1406-1418.
[14] Hou M, Xie JF, Kong XP, et al. Acupoint injection of onabotulinumtoxin A for migraines[J]. Toxins(Basel), 2015, 7(11): 4442-4454.
[15] Magnusson JE, Becker WJ. Migraine frequency and intensity: relationship with disability and psychological factors[J]. Headache, 2003, 43(10): 1049-1059.
[16] Fonfria E, Maignel J, Lezmi S, et al. The expanding therapeutic utility of botulinum neurotoxins[J]. Toxins(Basel), 2018, 10(5): 208.
[17] Martínez-Pías E, Guerrero ÁL, Sierra Á, et al. Daily headache in chronic migraine is a predictive factor of response in patients who had completed three sessions of onabotulinumtoxinA[J]. Toxins(Basel), 2021, 13(6): 432.
[18] Silberstein SD, Dodick DW, AuroraSK, et al. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT[J]. J Neurol Neurosurg Psychiatry, 2015, 86(9): 996-1001.
[19] Torres-Ferrus M, Gallardo VJ, Alpuente A, et al. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with onabotulinumtoxinA[J]. J Headache Pain, 2020, 21(1): 88.
[20] Ornello R, Guerzoni S, Baraldi C, et al. Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data[J]. J Headache Pain, 2020, 21(1): 40.
[21] Pijpers JA, Kies DA, van Zwet EW, et al. Behavioural intervention in medication overuse headache: a concealed double-blind randomized controlled trial[J]. Eur J Neurol, 2022, 29(5): 1496-1504.
[22] Ching J, Tinsley A, Rothrock J. Prognosis following discontinuation of OnabotulinumA therapy in “super-responding” chronic migraine patients[J]. Headache, 2019(59): 1279-1285.
[23] Pak AT, Üstün Ì, Sengul Y. Botulinum toxin type A wear-off phenomenon in chronic migraine patients: how long does the maximum efficiency last?[J]. ArqNeuropsiquiatr, 2021, 79(10): 886-890.
[24] Masters-Israilov A, Robbins MS. Onabotulinumtoxin A wear-off phenomenon in the treatment of chronic migraine[J]. Headache,2019, 59(10): 1753-1761.
[25] Armanious M, Khalil N, Lu Y, et al. Erenumab and onabotulinumtoxina combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis[J]. J Pain Palliat Care Pharmacother, 2021, 35(1): 1-6.
[26] Becker WJ. Botulinum toxin in the treatment of headache[J]. Toxins(Basel), 2020, 12(12): 803.